Shiva R Singhal, MD
Hematology/Oncology · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: Adventist Health Sonora · El Camino Health · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Singhal’s office at (650) 988-8338 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A126309 · Current
Licensed to practise in California · since 2013 · expires 2026-12-31 · University of Delhi, Lady Hardinge Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health SonoraSonora, CAAcute Care Hospital · Voluntary non-profit - Church · No emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 64% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Postoperative wound dehiscence rate: 3.5 (2.04 to 4.96) · 288 cases, Jul 2022 – Jun 2024Worse than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 1.3 (1 to 1.6) · 1,004 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.185, Oct 2024 – Sep 2025
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Adventist Health Sonora
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 0 better, 4 the same, 0 worse of 4 measures. Readmissions: 1 better, 7 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative wound dehiscence rateComplications and deaths | 3.5 (2.04 to 4.96) · 288 cases | Worse | Jul 2022 – Jun 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.3 (1 to 1.6) · 1,004 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.185 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.15 (0.14 to 2.16) · 582 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.5 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 182.91 (123.44 to 242.37) · 38 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.9 · 118 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9 · 125 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.7 · 236 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15 · 433 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 1,364 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.39) · 3,671 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.07 to 0.48) · 3,602 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.24 to 5.59) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.24) · 310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.59 (0.98 to 4.2) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.97 (0 to 16.16) · 306 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.72 (1.85 to 9.58) · 277 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 1.06) · 2,750 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.614 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.6 · 105 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 209 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 12.6 · 119 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -23.8 · 255 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -13.4 · 455 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 381 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6 (4.3 to 8.1) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.7 (9.1 to 14.7) · 328 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 106 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.3) · 1,835 cases | No different | Jan 2022 – Dec 2024 |
What patients said (326 patients answered, 21% of those asked)
| Cleanliness | 3 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 69% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 44% |
| "YES", patients would definitely recommend the hospital | 64% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 93% |
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$230,881
Medicare paid this office $230,881 for 388 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 322 | $131,261 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $57,798 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $13,254 | $143 |
| Telephone medical discussion with physician, 21-30 minutes | 69 | $13,058 | $115 |
| New patient visit (60+ min) | 51 | $8,483 | $166 |
Who their Medicare patients are
388 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 23% · Women 55% · Also on Medicaid 16% · Health risk score 1.88. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Coronary heart disease 35% · Cancer 35% · Diabetes 34% · Chronic kidney disease 32% · Atrial fibrillation 27% · Heart failure 26% · Depression 20% · COPD 15% · Dementia 12% · Stroke 11%.
The office billed $1,091,680, Medicare allowed $307,646 and paid $230,881; for 1,961 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 388 | 1,961 | 77 | 1.88 | $1,091,680 | $230,881 |
| 2023 | 385 | 2,335 | 77 | 2.16 | $1,265,724 | $274,902 |
| 2022 | 346 | 2,391 | 77 | 1.94 | $1,237,256 | $276,366 |
| 2021 | 316 | 2,599 | 77 | 2.06 | $1,250,317 | $303,079 |
| 2020 | 242 | 1,896 | 77 | 2.24 | $866,129 | $180,649 |
| 2019 | 244 | 1,474 | 78 | 1.94 | $689,861 | $147,981 |
| 2018 | 19 | 32 | 74 | 2.45 | $13,967 | $3,646 |
| 2015 | 16 | 23 | 70 | 2.31 | $6,918 | $1,714 |
| 2014 | 105 | 235 | 73 | 1.84 | $79,668 | $22,348 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 282 | $141,035 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 105 | $61,407 | $108 |
| Telephone medical discussion with physician, 21-30 minutes | 119 | $25,114 | $116 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $21,170 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $9,873 | $73 |
| New patient visit (60+ min) | 46 | $7,531 | $164 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,384 | $119 |
2022: 7 services
| Long return visit (40+ min) | 260 | $127,916 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 107 | $86,825 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 89 | $26,289 | $175 |
| Telephone medical discussion with physician, 21-30 minutes | 86 | $17,639 | $117 |
| New patient visit (60+ min) | 49 | $7,960 | $162 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,512 | $126 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,881 | $99 |
2021: 10 services
| Long return visit (40+ min) | 224 | $134,940 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 125 | $91,182 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 103 | $33,610 | $179 |
| Telephone medical discussion with physician, 21-30 minutes | 58 | $14,967 | $125 |
| Return visit (30+ min) | 72 | $7,819 | $74 |
| Hospital discharge day management, more than 30 minutes | 22 | $5,537 | $101 |
| New patient visit (60+ min) | 25 | $4,122 | $165 |
| Long return visit (40+ min) | 12 | $3,736 | $129 |
| New patient visit (45+ min) | 29 | $3,563 | $123 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,765 | $126 |
2020: 10 services
| Long return visit (40+ min) | 177 | $78,450 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $53,445 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 72 | $21,831 | $172 |
| Return visit (30+ min) | 64 | $9,211 | $69 |
| Telephone medical discussion with physician, 21-30 minutes | 34 | $5,716 | $97 |
| New patient visit (60+ min) | 21 | $2,876 | $137 |
| Hospital discharge day management, more than 30 minutes | 12 | $2,098 | $95 |
| Long return visit (40+ min) | 15 | $2,083 | $104 |
| New patient visit (45+ min) | 18 | $2,028 | $113 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $893 | $64 |
2019: 6 services
| Long return visit (40+ min) | 162 | $73,935 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 96 | $39,497 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $21,526 | $172 |
| New patient visit (60+ min) | 53 | $7,569 | $143 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,126 | $94 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 11 | $760 | $69 |
2018: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $1,837 | $84 |
2015: 1 service
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,322 | $73 |
2014: 2 services
| Long return visit (40+ min) | 90 | $17,538 | $89 |
| New patient visit (60+ min) | 30 | $4,078 | $136 |
Medicaid work
$458 in 2024
Medicaid paid $458 for 52 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 52 | $458 |
| 2024 | 52 | 1 | 14 | $458 |
| 2023 | 18 | 1 | 14 | $0 |
| 2018 | 206 | 6 | 25 | $6,911 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 18 | $0 |
2018
| Long return visit (40+ min) | 107 | $5,639 |
| Return visit (30+ min) | 30 | $1,168 |
| COMPREHENSIVE METABOLIC PANEL | 19 | $60 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 19 | $44 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 14 | $0 |
| Hospital outpatient clinic visit for assessment and management of a patient | 17 | $0 |
Drugs they prescribed that Part D paid
$2,938,274
Pharmacies billed $2,938,274 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (63 of 1,025) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%.
708 generic and fewer than 11 brand-name prescriptions · $2,938,274 in drug cost · 19 antibiotic prescriptions to 12 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 36 | $514,720 | $14,298 |
| Calquence | 26 | $425,150 | $16,352 |
| Tagrisso | 24 | $421,028 | $17,543 |
| Tibsovo | 12 | $397,453 | $33,121 |
| Lenvima | 11 | $270,732 | $24,612 |
See all 36 drugs
| Xtandi | 36 | $514,720 | $14,298 |
| Calquence | 26 | $425,150 | $16,352 |
| Tagrisso | 24 | $421,028 | $17,543 |
| Tibsovo | 12 | $397,453 | $33,121 |
| Lenvima | 11 | $270,732 | $24,612 |
| Jakafi | 15 | $263,676 | $17,578 |
| Revlimid | 15 | $184,149 | $12,277 |
| Eliquis | 102 | $77,730 | $762 |
| Fulphila | 12 | $24,268 | $2,022 |
| Xarelto | 24 | $23,366 | $974 |
| Abiraterone Acetate | 12 | $14,531 | $1,211 |
| Imatinib Mesylate | 19 | $14,156 | $745 |
| Enoxaparin | 18 | $4,908 | $273 |
| Anastrozole | 87 | $1,829 | $21 |
| Hydroxyurea | 55 | $1,425 | $26 |
| Tamoxifen Citrate | 18 | $851 | $47 |
| Acyclovir | 18 | $590 | $33 |
| Pantoprazole | 15 | $392 | $26 |
| Letrozole | 27 | $378 | $14 |
| Dexamethasone | 18 | $369 | $21 |
| Ondansetron Odt | 16 | $343 | $21 |
| Levothyroxine | 18 | $331 | $18 |
| Sertraline | 12 | $311 | $26 |
| Venlafaxine Hcl Er | 25 | $266 | $11 |
| Oxycodone | 20 | $264 | $13 |
| Hydrocodone-Acetaminophen | 18 | $262 | $15 |
| Warfarin | 17 | $243 | $14 |
| Prednisone | 28 | $188 | $7 |
| Gabapentin | 11 | $152 | $14 |
| Trazodone | 11 | $152 | $14 |
| Ropinirole | 14 | $138 | $10 |
| Ondansetron | 15 | $120 | $8 |
| Furosemide | 21 | $93 | $4 |
| Tramadol | 14 | $81 | $6 |
| Zolpidem | 17 | $47 | $3 |
| Lorazepam | 16 | $33 | $2 |
Year by year
| 2024 | 1,025 | 138 | 6% (63) | None | $2,938,274 |
| 2023 | 613 | 128 | 12% (72) | None | $1,321,566 |
| 2022 | 238 | 89 | 12% (28) | 32% | $512,934 |
| 2021 | 262 | 74 | 10% (25) | 17% | $166,730 |
| 2020 | 348 | 66 | 6% (19) | None | $263,312 |
| 2019 | 361 | 87 | 7% (24) | None | $260,832 |
| 2018 | 709 | 109 | 6% (40) | 11% | $745,934 |
| 2017 | 780 | 102 | 11% (83) | 16% | $815,907 |
| 2016 | 742 | 92 | 12% (88) | 24% | $844,300 |
| 2015 | 857 | 98 | 15% (129) | None | $512,295 |
| 2014 | 489 | 68 | 13% (65) | 15% | $247,398 |
| 2013 | 65 | 22 | None | None | $17,589 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Xtandi | 16 | $192,589 | $12,037 |
| Eliquis | 71 | $52,313 | $737 |
| Xarelto | 13 | $11,880 | $914 |
| Anastrozole | 40 | $1,292 | $32 |
| Tamoxifen Citrate | 14 | $1,000 | $71 |
| Hydroxyurea | 31 | $859 | $28 |
| Oxycodone | 20 | $373 | $19 |
| Levothyroxine | 13 | $294 | $23 |
| Potassium Chloride | 12 | $265 | $22 |
| Letrozole | 11 | $260 | $24 |
| Tramadol | 18 | $228 | $13 |
| Hydrocodone-Acetaminophen | 14 | $179 | $13 |
| Lorazepam | 24 | $136 | $6 |
| Furosemide | 24 | $96 | $4 |
| Prednisone | 23 | $75 | $3 |
2022: 5 drugs
| Revlimid | 12 | $205,575 | $17,131 |
| Xtandi | 14 | $194,217 | $13,873 |
| Eliquis | 32 | $17,424 | $545 |
| Hydroxyurea | 13 | $374 | $29 |
| Anastrozole | 12 | $235 | $20 |
2021: 3 drugs
| Potassium Chloride | 18 | $565 | $31 |
| Hydroxyurea | 22 | $416 | $19 |
| Prednisone | 17 | $73 | $4 |
2020: 4 drugs
| Xarelto | 11 | $9,091 | $826 |
| Potassium Chloride | 23 | $669 | $29 |
| Levothyroxine | 19 | $258 | $14 |
| Prednisone | 29 | $136 | $5 |
2019: 9 drugs
| Potassium Chloride | 28 | $850 | $30 |
| Anastrozole | 31 | $801 | $26 |
| Letrozole | 14 | $388 | $28 |
| Ondansetron | 23 | $271 | $12 |
| Prednisone | 32 | $175 | $5 |
| Hydrocodone-Acetaminophen | 11 | $149 | $14 |
| Pantoprazole | 17 | $112 | $7 |
| Warfarin | 11 | $100 | $9 |
| Lorazepam | 17 | $65 | $4 |
2018: 18 drugs
| Revlimid | 18 | $266,216 | $14,790 |
| Imbruvica | 14 | $163,330 | $11,666 |
| Zytiga | 13 | $140,390 | $10,799 |
| Tamoxifen Citrate | 28 | $1,684 | $60 |
| Anastrozole | 67 | $1,238 | $18 |
| Hydroxyurea | 26 | $992 | $38 |
| Dexamethasone | 26 | $880 | $34 |
| Ondansetron | 50 | $574 | $11 |
| Diphenoxylate-Atropine | 31 | $508 | $16 |
| Potassium Chloride | 30 | $469 | $16 |
| Hydrocodone-Acetaminophen | 16 | $422 | $26 |
| Prochlorperazine Maleate | 49 | $382 | $8 |
| Prednisone | 27 | $352 | $13 |
| Letrozole | 20 | $346 | $17 |
| Allopurinol | 12 | $294 | $24 |
| Warfarin | 27 | $288 | $11 |
| Lorazepam | 58 | $288 | $5 |
| Hydromorphone | 13 | $93 | $7 |
2017: 24 drugs
| Revlimid | 16 | $208,356 | $13,022 |
| Afinitor | 12 | $160,340 | $13,362 |
| Imbruvica | 11 | $124,575 | $11,325 |
| Xarelto | 12 | $4,643 | $387 |
| Fentanyl | 31 | $1,675 | $54 |
| Tamoxifen Citrate | 20 | $1,281 | $64 |
| Potassium Chloride | 18 | $825 | $46 |
| Anastrozole | 53 | $758 | $14 |
| Letrozole | 39 | $743 | $19 |
| Hydroxyurea | 23 | $638 | $28 |
| Acyclovir | 13 | $599 | $46 |
| Hydromorphone | 19 | $571 | $30 |
| Levofloxacin | 18 | $447 | $25 |
| Ondansetron | 40 | $444 | $11 |
| Diphenoxylate-Atropine | 22 | $405 | $18 |
| Lorazepam | 77 | $381 | $5 |
| Dexamethasone | 43 | $377 | $9 |
| Prochlorperazine Maleate | 52 | $369 | $7 |
| Omeprazole | 23 | $364 | $16 |
| Gabapentin | 12 | $298 | $25 |
| Loperamide | 12 | $156 | $13 |
| Oxycodone | 13 | $137 | $11 |
| Pantoprazole | 14 | $106 | $8 |
| Trazodone | 14 | $68 | $5 |
2016: 28 drugs
| Revlimid | 16 | $181,733 | $11,358 |
| Xalkori | 11 | $151,253 | $13,750 |
| Mekinist | 12 | $104,998 | $8,750 |
| Tafinlar | 12 | $95,392 | $7,949 |
| Neupogen | 11 | $15,415 | $1,401 |
| Xarelto | 23 | $8,394 | $365 |
| Enoxaparin | 16 | $6,157 | $385 |
| Arimidex | 11 | $5,330 | $485 |
| Fentanyl | 21 | $1,294 | $62 |
| Anastrozole | 43 | $913 | $21 |
| Potassium Chloride | 33 | $888 | $27 |
| Levofloxacin | 12 | $642 | $54 |
| Letrozole | 31 | $569 | $18 |
| Hydrocodone-Acetaminophen | 17 | $562 | $33 |
| Hydromorphone | 25 | $487 | $19 |
| Tamoxifen Citrate | 11 | $457 | $42 |
| Gabapentin | 15 | $363 | $24 |
| Hydroxyurea | 23 | $354 | $15 |
| Ondansetron | 29 | $340 | $12 |
| Omeprazole | 18 | $338 | $19 |
| Dexamethasone | 27 | $273 | $10 |
| Acyclovir | 13 | $199 | $15 |
| Lorazepam | 41 | $150 | $4 |
| Prochlorperazine Maleate | 23 | $144 | $6 |
| Zolpidem | 12 | $81 | $7 |
| Pantoprazole | 13 | $70 | $5 |
| Tramadol | 11 | $64 | $6 |
| Furosemide | 14 | $20 | $1 |
2015: 26 drugs
| Zytiga | 13 | $101,731 | $7,825 |
| Xarelto | 15 | $4,933 | $329 |
| Fentanyl | 24 | $1,857 | $77 |
| Potassium Chloride | 39 | $1,090 | $28 |
| Hydrocodone-Acetaminophen | 41 | $935 | $23 |
| Anastrozole | 35 | $778 | $22 |
| Ondansetron | 29 | $552 | $19 |
| Levofloxacin | 18 | $501 | $28 |
| Oxycodone | 33 | $498 | $15 |
| Dexamethasone | 30 | $430 | $14 |
| Metoprolol | 17 | $373 | $22 |
| Levetiracetam | 11 | $291 | $26 |
| Omeprazole | 18 | $273 | $15 |
| Morphine Sulfate | 13 | $262 | $20 |
| Lorazepam | 43 | $262 | $6 |
| Letrozole | 17 | $243 | $14 |
| Gabapentin | 16 | $226 | $14 |
| Hydroxyurea | 12 | $192 | $16 |
| Nystatin | 11 | $178 | $16 |
| Prochlorperazine Maleate | 31 | $170 | $5 |
| Prednisone | 18 | $156 | $9 |
| Zolpidem | 12 | $150 | $12 |
| Furosemide | 35 | $108 | $3 |
| Pantoprazole | 16 | $94 | $6 |
| Famotidine | 15 | $85 | $6 |
| Hydrochlorothiazide | 20 | $52 | $3 |
2014: 15 drugs
| Zytiga | 15 | $111,067 | $7,404 |
| Enoxaparin | 15 | $17,324 | $1,155 |
| Fentanyl | 22 | $1,699 | $77 |
| Levofloxacin | 17 | $935 | $55 |
| Hydrocodone-Acetaminophen | 34 | $705 | $21 |
| Potassium Chloride | 14 | $488 | $35 |
| Anastrozole | 17 | $305 | $18 |
| Dexamethasone | 19 | $196 | $10 |
| Gabapentin | 17 | $193 | $11 |
| Ondansetron | 15 | $175 | $12 |
| Prednisone | 15 | $130 | $9 |
| Prochlorperazine Maleate | 15 | $109 | $7 |
| Lorazepam | 20 | $98 | $5 |
| Furosemide | 11 | $51 | $5 |
| Hydrochlorothiazide | 11 | $45 | $4 |
2013: 1 drug
| Ondansetron | 11 | $270 | $25 |
Money from drug and device companies
$84 in 2025
| 2025 | 3 | 4 | None | $84 |
| 2024 | 2 | 5 | None | $79 |
| 2023 | 3 | 6 | None | $99 |
| 2022 | 1 | 17 | None | $165 |
| 2021 | 1 | 1 | None | $15 |
| 2020 | 6 | 8 | None | $168 |
| 2019 | 4 | 7 | None | $136 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 4 published payments
| Pfizer | Education · 2025-07-10 | Ibrance | $31 |
| Abbvie | Meals · 2025-05-20 | Lupron Depot | $26 |
| Kerecis | Meals · 2025-01-23 | Kerecis Surgiclose | $15 |
| Kerecis | Meals · 2025-01-06 | Kerecis Surgiclose | $12 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $79
| Smith+Nephew | Collagenase Santyl | $55 | 2 payments
|
| Kerecis | Kerecis Omega3 Surgiclose | $25 | 2 payments
|
2023: $99
| Kerecis | Kerecis Omega3 Surgiclose | $53 | 1 payment
|
| Pfizer | Ibrance | $25 | 1 payment
|
| Abbvie | Lupron Depot | $21 | 1 payment
|
2022: $165
| Kerecis | Kerecis Omega3 Surgiclose | $165 | 1 payment
|
2021: $15
| Myriad Genetic Laboratories | Myrisk | $15 | 1 payment
|
2020: $168
| Seagen | Adcetris | $54 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $36 | 2 payments
|
| Pfizer | Xtandi | $24 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| Celgene | Revlimid | $17 | 1 payment
|
| Foundation Medicine | Foundationone | $16 | 1 payment
|
2019: $136
| Incyte | Jakafi | $52 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $34 | 2 payments
|
| Seattle Genetics | None | $30 | 1 payment
|
| Pfizer | Xalkori | $20 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme Corporation · A Phase 3 Randomized, Placebo Controlled Study To Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab Mk 3475 With Or Without Lenvatinib E7080,Mk 7902 As First Line Intervention in Participants With Metastatic Nonsquamous Non Small Cell Lung Cancer Leap 006 · 2020 | Their institution | $57,293 |
| Merck Sharp & Dohme Corporation · A Phase 3 Randomized, Placebo Controlled Study To Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab Mk 3475 With Or Without Lenvatinib E7080,Mk 7902 As First-Line Intervention in Participants With Metastatic Nonsquamous Non Small Cell Lung Cancer Leap-006 · 2021 | Their institution | $56,130 |
| Merck Sharp & Dohme Corporation · A Phase 3 Randomized, Placebo Controlled Study To Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy Pembrolizumab Mk 3475 With Or Without Lenvatinib E7080,Mk 7902 As First Line Intervention in Participants With Metastatic Nonsquamous Non Small Cell Lung Cancer Leap 006 · 2019 | Their institution | $39,415 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1942456389
- Licence
- CA A126309California A126309: Current · expires 2026-12-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X)
- Mailing address
- 2505 Hospital Dr, Mountain View, CA, 94040
- NPI first listed
- 2008-08-18
- NPI last updated
- 2020-12-04
- NPI record certified
- 2020-12-04
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 700 Mountain Ranch Road, Sanandreas, CA, 95249